2[1]Nakashima M, Kurihara A, Hisaoka M. Prediction of human pharmacokinetics of panipenem, a new carbapenem antibiotics, from animal data [J]. Drugs Exp Clin Res, 1992, 18(9):371
3[2]Edwards J R. Meropenem: a microbiological overview [J]. J Antimicrob Chemother, 1995,36(Suppl A): 1
4[3]Shishido H, Nagai H, Kurashima A, et al. A study on in vitro antibacterial and clinical usefulness in respiratory tract infections of panipenem/oetarnipron, a newly synthesised carbapenem antibiotic [J]. Jpn J Antibiot, 1992,45(2): 143
5[4]Shimada K, Oka S, Goto M. Antimicrobioal activity of panipenem against Staphylococcus aureus and Pseudomonas aeruginosa in in vitro pharmocokinetic model in comparison with imipenem [J]. Chemotherapy (Tokyo), 1991,39 (Suppl 3) :75
6[5]Kimura T, Kokubun H, Nonatari M, et al. Population pharmacokinetics of panipenem in neonates and restrospective evaluation of dosage [J]. J Antimicrob Chemother, 2001,47 (1):51
9Waterer GW, Wunderink RG. Increasing threat of gram-negative bacteria[J]. Crit Care Med, 2001, 29, 4(Suppl): N75-81
10Mathai D, Lewis M T, Kugler KC, et al. Antibacterial activity of 41 antimicrobi als tested against over 2733 bacterial isolates from hospitalized patients with p neumonia: Results from the SENTRY antimicrobial surveillance program[J]. Di agn Microbiol Infect Dis, 2001, 39(2): 105-116
